4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-dihydropyridine-2-carbaldehyde | 586379-26-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-dihydropyridine-2-carbaldehyde
• 英文别名: 1-(2,6-difluorophenyl)-4-[(2,4-difluorophenyl)methoxy]-6-oxopyridine-2-carbaldehyde
• CAS: 586379-26-2
• 化学式: C₁₉H₁₁F₄NO₃
• 分子量: 377.295
• InChiKey: QMTGWXHGXZAEPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-dihydropyridine-2-carbaldehyde 在 sodium tetrahydroborate 、 N-氯代丁二酰亚胺 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 8.0h， 生成 3-chloro-4-[(2,4-difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-(hydroxymethyl)pyridine-2(1H)-one
  参考文献：
  名称：

  Design, synthesis and activity of a potent, selective series of N -aryl pyridinone inhibitors of p38 kinase

  摘要：

  A series of N-aryl pyridinone inhibitors of p38 mitogen activated protein (MAP) kinase were designed and prepared based on the screening hit SC-25028 (1) and structural comparisons to VX-745 (5). The focus of the investigation targeted the dependence of potency and metabolic stability on the benzyloxy connectivity, the role of the C-6 position and the substitution pattern on the N-phenyl ring. Further optimization produced the highly selective and potent pyridinones 2 and 3. These inhibitors exhibited activity in both acute and chronic models of inflammation. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.120
• 作为产物：
  描述：

  1-(2,6-Difluorophenyl)-4-[(2,4-difluorophenyl)methoxy]-6-methylpyridin-2-one 在 selenium(IV) oxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.5h， 生成 4-[(2,4-Difluorobenzyl)oxy]-1-(2,6-difluorophenyl)-6-oxo-1,6-dihydropyridine-2-carbaldehyde
  参考文献：
  名称：

  Design, synthesis and activity of a potent, selective series of N -aryl pyridinone inhibitors of p38 kinase

  摘要：

  A series of N-aryl pyridinone inhibitors of p38 mitogen activated protein (MAP) kinase were designed and prepared based on the screening hit SC-25028 (1) and structural comparisons to VX-745 (5). The focus of the investigation targeted the dependence of potency and metabolic stability on the benzyloxy connectivity, the role of the C-6 position and the substitution pattern on the N-phenyl ring. Further optimization produced the highly selective and potent pyridinones 2 and 3. These inhibitors exhibited activity in both acute and chronic models of inflammation. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.120

文献信息

• Substituted pyridinones
  申请人：Devadas Balekudru

  公开号：US20050176775A1

  公开（公告）日：2005-08-11

  Disclosed are compounds of Formula I and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , and R 5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.

  本发明涉及式I的化合物及其药学上可接受的盐，其中R1、R2、R3、R4和R5在此被定义。这些化合物可用于治疗由未调节的p38 MAP激酶和/或TNF活性引起或加剧的疾病和状况。本发明还涉及含有这些化合物的药物组合物、制备这些化合物的方法以及使用这些化合物的治疗方法。
• Diaryl substituted pyridinones
  申请人：Pfizer Inc

  公开号：US07629363B2

  公开（公告）日：2009-12-08

  Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3/R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.

  本发明涉及化合物I的公开式及其药学上可接受的盐，其中R1、R2、R3/R4和R5的定义如下。这些化合物可用于治疗由未受调节的p38 MAP激酶和/或TNF活性引起或恶化的疾病和病况。本发明还公开了含有这些化合物的药物组合物、制备这些化合物的方法以及使用这些化合物的治疗方法。
• SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE
  申请人：Pharmacia Corporation

  公开号：EP1490064A1

  公开（公告）日：2004-12-29
• US7067540B2
  申请人：——

  公开号：US7067540B2

  公开（公告）日：2006-06-27
• US7629363B2
  申请人：——

  公开号：US7629363B2

  公开（公告）日：2009-12-08